Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes

Leuk Lymphoma. 2018 Jan;59(1):233-236. doi: 10.1080/10428194.2017.1323269. Epub 2017 May 30.

Authors

Yang Zhang¹, Zhao Cheng², Wen-Zhe Yan², Su-Fang Liu², Chun-Hong Hu¹, Guang-Sen Zhang²

Affiliations

¹ a Department of Oncology , The Second Xiang-Ya Hospital, Central South University , Changsha , PR China.
² b Department of Hematology, Institute of Molecular Hematology , The Second Xiang-Ya Hospital, Central South University , Changsha , PR China.

PMID: 28554234
DOI: 10.1080/10428194.2017.1323269

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Amino Acid Sequence
Apoptosis Regulatory Proteins / genetics*
Base Sequence
Cadherins / genetics*
Dasatinib / therapeutic use*
Exome Sequencing
Fusion Proteins, bcr-abl / genetics*
Humans
In Situ Hybridization, Fluorescence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Male
Middle Aged
Mutation*
Protein Kinase Inhibitors / therapeutic use
Remission Induction

Substances

Apoptosis Regulatory Proteins
CDH10 protein, human
Cadherins
Protein Kinase Inhibitors
TP53BP2 protein, human
Fusion Proteins, bcr-abl
Dasatinib